Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 4233
Gene Symbol: MET
MET
0.100 Biomarker phenotype BEFREE Increased activity of these and the plasma protease, hepatocyte growth factor activator (HGFA), is associated with unregulated cell signaling and tumor progression through increased MET and RON kinase signaling pathways. 30571119 2019
Entrez Id: 4233
Gene Symbol: MET
MET
0.100 Biomarker phenotype BEFREE The role of aberrant hepatocyte growth factor receptor (c-MET, also known as tyrosine-protein kinase MET)/hepatocyte growth factor (HGF) signaling in cancer progression and invasion has been extensively studied. c-MET inhibitors have shown promising pre-clinical and early phase clinical trial anti-tumor activity in several tumor types, although results of most phase III trials with these agents have been negative. 30649748 2019
Entrez Id: 4233
Gene Symbol: MET
MET
0.100 AlteredExpression phenotype BEFREE Aberrant HGF/c-MET upregulation and activation is frequently observed in bladder cancer correlating with cancer progression and invasion. 31554791 2019
Entrez Id: 4233
Gene Symbol: MET
MET
0.100 Biomarker phenotype BEFREE Activation of hepatocyte growth factor (HGF) by proteolytic processing is triggered in cancer microenvironments, and subsequent signaling through the MET receptor is involved in cancer progression. 31101918 2019
Entrez Id: 4233
Gene Symbol: MET
MET
0.100 Biomarker phenotype BEFREE circ5912 suppresses cancer progression via inducing MET in bladder cancer. 31808751 2019
Entrez Id: 4233
Gene Symbol: MET
MET
0.100 Biomarker phenotype BEFREE Here, we discuss the role of the MET/HGF axis in tumor progression and dissemination considering as a model pancreatic cancer, and provide a proof of concept for the application of dual MET/HGF inhibition as an adjuvant therapy in pancreatic cancer patients. 30544501 2018
Entrez Id: 4233
Gene Symbol: MET
MET
0.100 Biomarker phenotype BEFREE MET and RON have been found to be increased in a variety of tumors and to be associated with tumor progression and acquired resistance to therapy. 30015968 2018
Entrez Id: 4233
Gene Symbol: MET
MET
0.100 Biomarker phenotype BEFREE This review shows a molecular aspect of NSCLC biomarkers used in clinical approaches, such as EGFR, KRAS, MET, indicating mutations that are crucial for cancer progression and related to treatment properties. 30147015 2018
Entrez Id: 4233
Gene Symbol: MET
MET
0.100 Biomarker phenotype BEFREE Background Both MET and c-SRC are important mediators of cancer progression and there is cross talk between the two molecules. 29047029 2018
Entrez Id: 4233
Gene Symbol: MET
MET
0.100 Biomarker phenotype BEFREE MET, a <i>c-met</i> proto-oncogene product and hepatocyte growth factor (HGF) receptor, is known to play an important role in cancer progression, including bone metastasis. 29890660 2018
Entrez Id: 4233
Gene Symbol: MET
MET
0.100 Biomarker phenotype BEFREE Interconversions between epithelial and mesenchymal states, often referred to as epithelial mesenchymal transition (EMT) and its reverse MET, play important roles in embryonic development and are recapitulated in various adult pathologies including cancer progression. 28789987 2018
Entrez Id: 4233
Gene Symbol: MET
MET
0.100 AlteredExpression phenotype BEFREE These findings suggest that c-MET overexpression in HA is not an early event in hepatocarcinogenesis, but constitutes a divergent molecular pathway leading to neoplastic change compared to overexpression observed in the late stages of tumour progression. 29256857 2017
Entrez Id: 4233
Gene Symbol: MET
MET
0.100 Biomarker phenotype BEFREE These findings reveal the therapeutic potential of targeting the HGF/MET pathway for inhibition, to constrain tumor progression of SCLC cells showing aberrant activation of HGF/MET signaling. 28474864 2017
Entrez Id: 4233
Gene Symbol: MET
MET
0.100 AlteredExpression phenotype BEFREE The hepatocyte growth factor receptor; also known as mesenchymal-epithelial transition factor (c-Met) and its ligand hepatocyte growth factor (HGF) are overexpressed in head and neck squamous cell carcinoma (HNSCC); and regulates tumor progression and response to therapy. 29231907 2017
Entrez Id: 4233
Gene Symbol: MET
MET
0.100 Biomarker phenotype BEFREE Hepatocyte growth factor receptor (HGFR, c-Met) is an essential member of the receptor tyrosine kinase (RTK) family that is often dysregulated during tumor progression, driving a malignant phenotypic state and modulating important cellular functions including tumor growth, invasion, metastasis, and angiogenesis, providing a strong rationale for targeting HGF/c-Met signaling axis in cancer therapy. 28902178 2017
Entrez Id: 4233
Gene Symbol: MET
MET
0.100 Biomarker phenotype BEFREE These studies also demonstrate that mutationally activated MET plays a significant role in a wide range of cancers and RTKs can promote tumor progression through diverse mechanisms. 28603720 2017
Entrez Id: 4233
Gene Symbol: MET
MET
0.100 Biomarker phenotype BEFREE C-MET and phospho-MET overexpression occurred preferentially in ADCs and in areas involved in tumor progression, in support of the view that MET activation plays a role in the development of an invasive phenotype in NSCLC. 28098570 2017
Entrez Id: 4233
Gene Symbol: MET
MET
0.100 Biomarker phenotype BEFREE However, despite increasing data supporting a link between MET, irradiation, and cancer progression, no data regarding the combination of MET-targeting agents and radiotherapy are available from the clinic. 28619752 2017
Entrez Id: 4233
Gene Symbol: MET
MET
0.100 Biomarker phenotype BEFREE Due to its role in tumor progression and therapeutic resistance, both HGF and MET have emerged as valid therapeutic targets. 28420162 2017
Entrez Id: 4233
Gene Symbol: MET
MET
0.100 Biomarker phenotype BEFREE We have shown that SOCS1 inhibits MET receptor kinase signaling, a key oncogenic pathway in cancer progression. 27779203 2017
Entrez Id: 4233
Gene Symbol: MET
MET
0.100 AlteredExpression phenotype BEFREE Aberrant activation of c-Met resulting from MET amplification and c-Met overexpression is associated with poor clinical outcome in multiple malignancies underscoring the importance of c-Met signaling in cancer progression. 26879245 2016
Entrez Id: 4233
Gene Symbol: MET
MET
0.100 Biomarker phenotype BEFREE To investigate how elevated stromal tRNAi(Met) contributes to tumor progression, we generated a mouse expressing additional copies of the tRNAi(Met) gene (2+tRNAi(Met) mouse). 26948875 2016
Entrez Id: 4233
Gene Symbol: MET
MET
0.100 Biomarker phenotype BEFREE Mounting studies highlighted the essential role of the HGF/c-MET axis in driving HCC tumor progression. 25607934 2015
Entrez Id: 4233
Gene Symbol: MET
MET
0.100 Biomarker phenotype BEFREE The MET and RON receptors are tyrosine kinases that form a non-covalent complex on the cell surface that functions in several steps of tumor progression. 25874493 2015
Entrez Id: 4233
Gene Symbol: MET
MET
0.100 Biomarker phenotype BEFREE Median time to tumor progression was 2.3 months (range, 0.4-19.7) for all treated patients with no responses in patients with a MET abnormality or single-agent c-MET inhibitor treatment. 25087088 2015